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The absence of preexisting neutralizing antibodies specific for the
novel A (H7N9) influenza virus indicates a lack of prior human
exposure. As influenza A virus–specific CD8+ T lymphocytes (CTLs)
can be broadly cross-reactive, we tested whether immunogenic
peptides derived from H7N9 might be recognized by memory CTLs
established following infection with other influenza strains. Prob-
ing across multiple ethnicities, we identified 32 conserved epitopes
derived from the nucleoprotein (NP) and matrix-1 (M1) proteins.
These NP and M1 peptides are presented by HLAs prevalent in
16–57% of individuals. Remarkably, some HLA alleles (A*0201,
A*0301, B*5701, B*1801, and B*0801) elicit robust CTL responses
against any human influenza A virus, including H7N9, whereas eth-
nicities where HLA-A*0101, A*6801, B*1501, and A*2402 are prom-
inent, show limited CTL response profiles. By this criterion, some
groups, especially the Alaskan and Australian Indigenous peoples,
would be particularly vulnerable to H7N9 infection. This dissection
of CTL-mediated immunity to H7N9 thus suggests strategies for
both vaccine delivery and development.
CD8 T cells | HLA types
Emerging unexpectedly in February 2013, the H7N9 influenzaA virus (IAV) has thus far caused 137 human infections with
45 deaths (1). Clinical manifestations include major respiratory
compromise, multiorgan failure, and exceedingly high serum
cytokine and chemokine levels (2). Although May through
September saw only five such cases, two more were recorded
in October (1), indicating that H7N9 may return during the
northern winter. Furthermore, the presence of a natural avian
reservoir and the severity of the disease emphasized the need to
focus on protective immunity. Most patients had contact with
poultry within a week before clinical onset (2), suggesting that
domestic birds are the source (2, 3). Even so, the potential for
person-to-person spread is highlighted by ferret experiments (4)
and instances of infection via close family contact (3). A very real
concern is that further mutations may facilitate human-to-human
transmission (5).
Evidence from animal (6) and human studies (7–9) suggests
that, in the absence of neutralizing antibodies (NAbs), preexist-
ing memory CD8+ T lymphocytes (CTLs) directed at conserved
and/or cross-reactive IAV peptide + class I HLA (pHLA1)
epitopes can diminish disease severity. The recall of IAV-specific
CTLs promotes recovery manifested by milder symptoms, di-
minished virus shedding and transmission (6, 7). A comprehen-
sive analysis of the 2009 pandemic H1N1 IAV (H1N1pdm-2009)
indicated that CTL memory provided some protection for the
antibody naïve (9). Thus, cross-reactive CTL memory generated
after a prior encounter with seasonal or pandemic IAVs, or by
a CTL-directed vaccine, could potentially limit the severity of an
H7N9 pandemic.
The present analysis probes the extent of preexisting CTL im-
munity in populations that have not been exposed to the H7N9
virus. This potential for CTL recall is defined for HLA1s that are
differentially prominent in various ethnicities. Using an evolu-
tionary and immunological approach, we show substantial levels
of immunogenic peptide conservation for nucleoprotein (NP)
and matrix-1 (M1), with estimated coverage according to known
HLA1 presentation profiles ranging between 16% and 57% of the
global population. Overall, the findings support the view that it
is important to consider developing vaccines with a T cell–based
component that has the potential to protect against severe novel
IAV infections. Furthermore, given that some ethnicities, including
Australia’s Indigenous and Alaskan people, show evidence of a
diminished HLA1-related response capacity, it is essential that
health policy development and planning gives such groups pri-
ority in IAV vaccination campaigns. The 2009 H1N1 pandemic
caused higher attack rates and morbidity among Indigenous pop-
ulations in the Americas, New Zealand, and Australia (10).
Results
Conservation of CTL Antigenic Regions in the Novel H7N9 Virus. The
first step was to establish which known immunogenic IAV
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peptides are conserved within H7N9, using IAVs that caused
major human pandemics or epidemics as a reference (Table S1).
Included were the pandemic H1N1-1918 A/Brevig Mission/1,
H2N2-1957 A/Japan/305, H3N2-1968 A/Hong Kong/16 and H1N1-
2009 A/Auckland/viruses, and seasonal H1N1 IAVs from 1933,
1983, and 2006. Our focus was on peptides from the prominent NP
and M1 (11, 12) proteins, as identified in the Immune Epitope
Database (www.immuneepitope.org). We found a substantial level
of conservation within NP (Fig. 1A) and M1 (Fig. 1B) with respect
to H7N9-derived pHLA1 epitopes (Fig. 1). Analysis of 76 NP
peptides established that 12 were conserved (Table S2), whereas 18
were unique to H7N9 and had not been found previously (Table
S3). The remaining 46 were classified as variable (Fig. 1A), meaning
that they are shared by at least one IAV isolated before the advent
of H7N9-2013 (Table S4). Evidence of such conservation was even
higher for M1 (Fig. 1B). Of 39 peptides, 20 were conserved, 9 were
unique to H7N9, and 10 variable (Tables S5–S7). Remarkably, all
14 immunogenic peptides within M147–88 have been conserved over
the last century, suggesting that this M1 region could be a target for
a universal CTL vaccine.
Mapping Conserved NP and M1 Peptides Across All IAV Lineages. To
confirm the conservation of the NP and M1 peptides across all
human IAVs, including H1N1 (1918–1957, 1977–2009, and 2009–
2013), H2N2 (1957–1968), and H3N2 (1968–2013), we identified
the established, nonsynonymous amino acid (aa) changes (Fig. 2,
gray bars). Then, immunogenic CTL peptides were deposited onto
this map, according to the conserved, unique, and variable no-
menclature (Tables S2–S7). The epitopes within NP and M1 that
do not fall on the variable bars show regions that have not evolved
in human IAVs over the last century, indicating that they are
functionally important for virus survival. Interestingly, this con-
firms that the conserved epitopes, identified in Fig. 1, have not
changed in other human viruses (except for NP259; in green).
Conversely, the variable (red) and unique (blue) epitopes are
found predominantly in the variable-gray regions (Fig. 2). Phylo-
genetic analysis highlights the avian origins of the H7N9 NP and
M1 genes (Fig. S1). Interestingly for M1, H7N9 is closely related
to the H1N1pdm-2009 IAVs that are well established in humans
(Fig. S1B), indicating a higher prevalence of shared peptides than
for NP. The close phylogenetic relationship to avian IAVs further
suggests that CTL epitope–based vaccines designed for H7N9
might confer protection against other avian IAVs (H5N1 and
H9N2) that occasionally infect humans.
Recall Potential of Memory CTLs Specific for Conserved H7N9 Peptides.
Based on the conservation analysis (Figs. 1 and 2), we dissected
human CTL immunity toward the H7N9 IAV by probing reactivity
to conserved, unique, and selected variable immunogenic pep-
tides. We first characterized the recall potential of preexisting
memory pools specific for conserved H7N9 peptides. The
analysis focused predominantly on NP, the major target for
immunodominant CTL responses (11) and the highly conserved,
immunodominant A*0201-restricted M158–66. The conserved NP
epitopes included A*0301-NP265–273, B*2705-NP383–391, B*5701-
NP199–207, B*1801-NP219–228, B*0801-NP225–233, B*0702-NP172–181,
and A*2402-NP39–47 (Fig. 3). We classified the WT form of the
NP383–391 peptide (found in H7N9) that binds B*2705 as conserved,
although an escape mutant is prominent in H3N2 strains (13).
To unravel the recall potential of preexisting CTL memory to the
H7N9 virus, peripheral blood mononuclear cells (PBMCs) obtained
from healthy adults expressing a spectrum of HLAs were stimu-
lated with the relevant conserved antigenic peptides for 10 d. The
presence and frequencies of peptide-specific CTLs across multiple
donors were then determined by an IFN-γ/TNF-α production
(Fig. 3).








+ (Fig. 3 A–F). For
these immunogenic peptides, all donors (n = 42) displayed
specific CTL responses. In contrast, we did not detect any CTLs
specific for B*0702-NP172 or A*2402-NP39 (Fig. 3 G and H),
both classified as conserved. This suggests that, although the
peptides may be conserved, these are weak epitopes that do not
elicit CTL reactivation. At least for B*0702, this could reflect
preferential presentation of immunodominant (but highly vari-
able) variants of NP418 (14) (see below). As a consequence,
B*0702+NP172 may be subdominant and unlikely to play a major
role in IAV-specific CTL immunity.







+NP225 (Fig. 3) displayed a ro-
bust functional potential and were detected at frequencies com-
parable to those found for the prominent A*0201+M158–66 CTL
epitope (Fig. 3B). This indicates that a substantial proportion (16–
57%; Table 1) of the human population should have preexisting
CD8+ CTLs that can respond to the H7N9 IAV. With ethnic
differences in mind, we estimated population coverage based on
the HLA types that present known, conserved immunogenic
H7N9 NP and M1 peptides. Clearly, the extent of such CTL im-
munity to H7N9 varies considerably across ethnicities (African,
37%; Caucasoid, 57%; Oriental, 37%; Amerindian, 36%; In-
digenous Alaskans and Indigenous Australian, 16%). This sug-
gests that both the potential to recruit established CTL immunity
and disease severity could show a clear ethnic bias in the face of an
H7N9 pandemic.
Fig. 1. High level of conservation for H7N9 CTL
peptides. CTL antigenic peptides within (A) NP and
(B) M1 were obtained from the Immune Epitope
Database (IEDB, www.iedb.org; April 2013) and
analyzed using the IEDB’s Epitope Conservancy
Analysis tool (http://tools.immuneepitope.org/tools/
conservancy/iedb_input). (C) Summary of numbers
and percentages of conserved, unique and variable
epitopes within NP and M1. Conservation at 100%
match was determined by comparing the corre-
sponding CTL peptides in H7N9 to those of repre-
sentative strains that have circulated in the human
population (Table S1). Black, CTL peptides conserved
over the last century; red, variable epitopes; *,
unique CTL peptides for the H7N9 IAV; white,
conserved H7N9-NP383 peptide that binds to
HLA-B*2705 (escape mutants were identified in
H3N2 strains for NP383).






























Lack of Established CTL Responses to Unique H7N9 Peptides.We then
examined CTL responses to the antigenic peptides unique to the
H7N9 virus (Table S3). Although human populations that have
not previously encountered H7N9 would likely see these pHLA1s
as novel, there is also the possibility that there could be some
“plasticity” in the cross-recognition of antigenic variants (15, 16).
We thus screened unexposed individuals for responses to unique
H7N9 epitopes, A*0101-NP44–52 (Fig. 4 A and B), A*6801-NP89–101
(Fig. 4G), and the NP37–54, NP373–390, and NP397–414 presented
by B*1501 (Fig. S2). PBMCs expressing a spectrum of HLAs
were cultured with either the H7N9 peptide(s) or peptides from
other human IAVs. Analysis of the normally immunodominant
Fig. 2. CTL peptide map for NP and M1 across all human IAV lineages. The analyses spanned the full protein-coding region of the NP and M1 proteins to
deduce changes in the conserved, unique and variable epitopes (Tables S2–S7). Green, blue, and red bars on the left of the peptides refer to conserved,
unique, and variable CTL peptides, respectively. The horizontal gray bars throughout the alignments highlight the nonsynonymous substitutions established
in H1N1, H2N2, and H3N2 viruses through their evolutionary history in human population. CTL peptides within (A) NP and (B) M1, which do not fall on the
gray bars, show regions that have not changed in human influenza A viruses (the exception being NP259), indicating lesser selection pressure on those sites.
Table 1. Estimation of the population coverage according to the HLA restriction of conserved epitopes in H7N9
Peptide(s) Restriction
Population coverage across ethnicities
Caucasoid* North American natives† Oriental* African* Amerindian* Alaskan Yupik‡ Australian Aboriginals§
M158–66 HLA-A2 25 21.66 27.17 15.76 24.78 2.3 12.7
NP265–273 HLA-A3 11.9 6.6 3.26 6.48 3.98 0.1 1.4
NP383–391 HLA-B27 3.71 8.5 3.62 1.46 4.98 13.28 0.1
NP199–207 HLA-B57 2.91 3 1.33 3.96 0.68 0 0.5
NP219–228 HLA-B18 6.31 2 0.92 4.62 0.5 0.6 0.2
NP225–233 HLA-B8 7.41 3.7 1.4 4.83 1.1 0.4 1.2
Total 57.24 45.46 37.7 37.11 36.02 16.7 16.1











































A*0101-NP44–52 showed that the H7N9-specific substitution at p9
(Y9N) was not recognized by CTLs that respond to either
H1N1pdm-2009 NP44 or to the seasonal NP44-S7N variant (Fig. 4 A
and B). Furthermore, preestablished HLA-A*0101+NP44–specific
memory CTLs do not recognize the Y9H variant of H3N2, in-
dicating that that any mutation at p9 leads to immune escape.
To understand the molecular basis of the cross-reactivity (with
WT) of H7N9-NP44-S7N vs. evasion by the H7N9-NP44-Y9N and
H7N9-NP44-Y9H variants, we analyzed thermal stability and
crystal structures for HLA*A0101 in complex with NP44 variants
(Fig. 4 C–F). The NP44–52 (WT) and NP44-S7N are comparable
in their capacity to stabilize the HLA-A*0101 molecule, with
a thermal melt point of 58.2 °C and 59.5 °C (Fig. 4C). However,
the p9 mutations reduced the stability of the pHLA1 by 10 °C
(Fig. 4C), most likely as a result of the large, aromatic Tyr being
replaced with a smaller Asn or a charged His. In addition, the
refold yield of HLA-A*0101 in the presence of NP44-Y9H and
NP44-Y9N was decreased by 50×, thereby precluding structural
studies. Thus, the reduced thermal stability of the NP44-Y9N
(H7N9) and NP44-Y9H (H3N2) complexes likely results in re-
duced peptide presentation and immunogenicity. Further de-
termination of HLA*A0101 crystal structures allowed precise
definition of the cross-reactivity between the NP44-WT and the
seasonal NP44-S7N. Structural analysis (Table S8) of NP44-WT
and NP44-S7N bound to HLA-A*0101 (resolution of 2.4 and 2.0
Å) show that NP44-WT adopts a classical extended conformation
in the antigen-cleft of HLA-A*0101 (Fig. 4D) (17). The P2-Thr
and P9-Tyr are buried, acting as anchor residues along with the
P6-Leu. The P3-Glu is partially buried in the D pocket and forms
a salt bridge with the Arg156. The P4-Leu, P5-Lys, and P8-Asp
are solvent exposed and represent potential contact points for
the T cell receptor (TCR) (Fig. 4D). The substitution at p7
Ser→Asn did not affect the conformation of the peptide within
the antigen-binding cleft (Fig. 4E). Overall, analyzing stability
and structure for the NP44 variants shows that, although NP44-S7N
does not change either parameter when bound to HLA-A*0101,
the variations at p9 within NP44-Y9N-H7N9 or NP44-Y9H-H3N2
drastically decrease the stability of the pHLA1 complex, with
a consequent loss of T-cell recognition.
To understand whether CTLs can recognize any of the other,
unique H7N9 peptides, we analyzed those with the capacity to
bind A*6801 and B*1501. It seems that, although CTLs are in-
duced by a spectrum of IAV NP89 variants, the A*6801-NP89-
H7N9 is not recognized by these memory sets (Fig. 4G). Thus,
H7N9-NP89 is an escape variant in the 1–9% of the population
that expresses HLA-A*6801. Similarly, the NP37, NP373, and
NP397 presented by HLA-B*1501 did not induce any responses
(Fig. S2), although IAV-specific CTLs directed at other immuno-
dominant epitopes, HLA-A*0301-NP265 (Fig. S2; D15-1 and D15-
2) and HLA-A*0201 M158 (Fig. S2; D15-3), were readily detected.
Overall, our analysis of the potentially immunogenic NP and
M1 peptide variants unique to H7N9 indicates that individuals
expressing HLA-A*0101, HLA-A*6801, and HLA-B*1501 will
lack preexisting memory CTLs capable of recognizing epitopes
defined by those HLA1 types. The H7N9-NP44-Y9N variant is
within an immunodominant epitope in HLA-A*0101+ individu-
als, with this immunoevasion affecting the 1–14% of individuals
with that HLA type, depending on ethnicity. In contrast, the
nonantigenic A*6801-NP89 H7N9 variant would affect 1–9% of
the population expressing A*6801. We found no CTL responses
to any of the B*1501 variants tested (Fig. S2).
CTL Cross-Reactivity for the Variable B*3501- and B*0702-NP418 Epitope.
Having assessed preexisting CTL immunity to conserved and
unique (to H7N9) epitopes, we then analyzed the peptides that
can be shared with H7N9 and are variably expressed in different
IAVs (Table S4). The extent of any such cross-reactivity would
depend on the influenza infection history. Interestingly, the vari-
able peptides within H7N9 most closely resemble those of the
pandemic H1N1-1918 virus (Table S4). This is evident from the
minimal aa differences in key peptides from the H7N9 and H1N1-
1918 strains (Fig. S3). Indeed, the H7N9 variant of the immuno-
dominant NP418 peptides presented by the large B7 family (15, 16)
was identical to that within the 1918-H1N1 virus and closely re-
sembled that from H1N1pdm-2009 (Table S4). In agreement with
our previous data (16), this H7N9-NP418 variant is not recognized
by memory CTL specific for the various seasonal influenza types
from the last decades (Fig. S4B). Tetrameric complexes of HLA-
B*0702 and HLA-B*3501 with different NP418 peptides were used
to stain PBMCs stimulated in vitro with a pool of 12 NP418 var-
iants. The H7N9 variant of the B*3501-NP418 tetramer showed
none to minimal cross-reactivity for CTLs stimulated with the
NP418 peptides expressed by recently circulating IAVs (Fig. S4).
Prior exposure to the pandemic H1N1pdm-2009 may, however,


























































































Fig. 3. CTL responses to conserved immunodominant H7N9 peptides.
PBMCs from healthy donors were peptide-stimulated and cultured for 10 d.
CTL responses were determined by an IFNγ/TNFα intracellular cytokine staining
(ICS). Representative FACS plots for (A) A*0301+NP265, (B) A*0201
+M158, (C)
B*2705+NP383, (D) B*5701
+NP199, (E ) B*1801
+NP219, (F ) B*0801
+NP225, (G)
B*0702+NP172, and (H) A*2402
+NP39 are shown. Values for no peptide are in
brackets. Graphs show pooled data from multiple donors. Background (no
peptide controls) was subtracted.






























Thus, our data suggest that there is the potential for a rapidly
spreading H7N9 IAV to recall robust, immunodominant, CD8+
CTL memory in substantial numbers of people (average of 35%
across multiple ethnicities, range 16–57%; Table 1). Even so,
although that may ameliorate influenza disease and reduce viral
spread for some individuals and groups, it is also the case that
such cross-reactivity is not found for certain HLA types that are
prevalent in what may be extremely vulnerable populations.
Discussion
Although human cases of the newly emerged H7N9 virus are
thought to have resulted primarily from contact with infected
birds, the genetic characteristics of this virus raise real concerns
that a mutant could readily emerge to cause efficient human-to-
human spread. As we have no prior history with this pathogen,
individuals of all ages would be susceptible. In the absence of
protective NAbs, evidence from both human studies and animal
experiments suggests that IAV-specific CD8+ CTL immunity
promotes more rapid recovery and milder disease (6–9). Hence,
cross-reactive CTL memory pools generated by previous in-
fection with seasonal or pandemic IAVs could potentially pro-
vide some protection against an H7N9 pandemic. The present
analysis focuses on the capacity of CD8+ T cells primed by in-
fection with currently circulating and past H1N1 and H3N2 IAVs
to respond to peptides that are shared with, or unique to, the
H7N9 virus. Our sequence, phylogenetic, and immunologic
analyses show that 28% of the CTL peptides within the immu-
nogenic NP and M1 proteins are conserved between the IAVs of
interest, 49% are found variably in that spectrum, and 23% are
unique to H7N9. Studies are underway to understand whether
the stability of certain regions within the viral NP and M1 results
from ineffective CD8+ T-cell immunity or the functional neces-
sity for the influenza virus.
Perhaps of greater significance is the recognition that some
HLA1 alleles present conserved IAV peptides. Strong represen-
tation of HLA A*0201, A*0301, B*5701, B*1801, and B*0801 in
any ethnic group is predictive of preexisting CTL memory, and
thus protection, following challenge with a novel IAV. Conversely,
individuals with HLA-A*0101, A*6801, B*1501, and A*2402 may
have little, if any, evidence of established CTL immunity to, for
example, the H7N9 virus. Interestingly, HLA1 has been the one
parameter repeatedly associated with HIV control, with B57 and
B27 being the most protective, whereas the converse is true for
B*35 and B*53 (18). Although we have tested preexisting CD8+
T-cell immunity to H7N9 in a vast number (n = 59) of samples
(n = 42 for Fig. 3; n = 10 for Fig. 4; n = 7 for Figs. S1–S4), the
donors displayed a number of HLAs, which made the sample size
for each HLA smaller. Further studies need to dissect influenza-
specific CTLs in a larger number of donors corresponding to
specific HLAs across different ethnicities.
The present analysis thus adds to other insights indicating that
the impact of established IAV CTL immunity should be analyzed
across different ethnicities (19). Thus far, H7N9 infection has
been limited to the ethnic Chinese population. The overall con-
servation of CTL antigenic peptides within H7N9 is 35%, rang-
ing between 57% (Caucasoid), 38% (Oriental), 37% (African),
16% (Australian Aboriginals), and 16% (Alaskan Natives),
making the latter two groups most vulnerable to H7N9 chal-
lenge. This is consistent with the high adult mortalities (up to
100%) for isolated Alaskan villages in the 1918–1919 pandemic
(20). Similarly, the Indigenous Australians were highly suscep-
tible to the A/H1N1 pandemic viruses in 1918 (21) and 2009
(10). As many as 10–20% died in 1919 (21) vs. <1% of other
(predominantly Caucasian) Australians. Hospitalization and
morbidity rates for the Indigenous were also greatly increased in
the recent 2009 A/H1N1 pandemic (22, 23), with 16% of hospi-
talized patients being from those communities. Although this may
reflect a combination of factors, including household crowding, a
high prevalence of comorbidities, and difficulties in accessing
healthcare, the relative lack of HLA1s that present conserved IAV
peptides may also be a contributing factor.
Close to 50% of the immunogenic H7N9 NP peptides are
found with variable prevalence in other IAVs known to have
established CTL memory in human populations. With both the
H1N1pdm-2009 virus and H7N9, it is intriguing that the variable
CTL peptides more closely resemble those from the pandemic
H1N1-1918 than from recently circulating H1N1 (before 2009)
and H3N2 influenza strains. Sequence analysis of the “resur-
rected” H1N1-1918 influenza virus indicates that this pathogen
was, indeed, avian derived. It also seems that the 1918 NP sur-
vived and remained stable in the swine influenza reservoir, to
emerge again in the H1N1pdm-2009 virus. Similarly, evolution-
ary analysis of H7N9 shows that all gene segments are of avian
origin (24).
From our analysis, it seems that memory CTLs specific for
prominent variable peptides (like NP418) from recently circulating
Fig. 4. H7N9 escape mutants for A*0101-NP44 and A*6801-NP89. (A–F) The Y9N mutation in the immunodominant H7N9 NP44 peptide abrogates CTL rec-
ognition by reducing thermal stability. (A) Representative FACS plots for CTL responses to different A*0101-NP44 variants. (B) CTL responses (IFNγ ICS, n = 7)
against four NP44 variants. (C) Thermal stability for the A*0101-NP44 variants. (D and E) Crystal structures of HLA-A*0101 (cartoon) bound to the NP44-WT
peptide (pink) and to the NP44-S7N peptide (orange), respectively. Only the α1-helix of the HLA is shown for clarity. (F) Superposition of the HLA-A*0101
binding cleft to NP44-WT (pink) and NP44-S7N (orange), with the Arg156 and Trp147 of the HLA represented in stick; the H bond shown as dashed lines. (G) An
ICS response to a unique H7N9 peptide NP89 restricted by HLA-A*6801, following stimulation with the NP89-H7N9 variant or a pool of NP89 seasonal and
pandemic variants (Table S4). Confirmation of prior IAV exposure was determined by assessing the reactivity to A*0201-M158.






































seasonal strains would not recognize a large proportion of the
variable H7N9-derived peptides in any pandemic situation. A
major variant that does not stimulate preexisting CTLs is the
H7N9-Y9N substitution of HLA-A*0101-NP44. This mutation
to an anchor residue at peptide P9 greatly destabilizes the
pHLA complex, compromises CTL binding/accessibility, and
can lead to viral escape, similar to what occurs in a mouse
model (25).
Overall, the level of CTL peptide conservation within the
H7N9 NP and M1 proteins appears to be lower than the 70–80%
found previously for the swine-derived H1N1pdm-2009 (26).
Lower CTL epitope conservation may partly explain the relative
severity of H7N9 influenza in ethnic Chinese, with 37% pop-
ulation coverage of cross-reactive HLA types. Infection out-
comes in known H7N9 cases were far from uniform. Some
recovered within a few days, whereas others required steroid
treatment, intensive care unit admission (75%), and mechanical
ventilation (86%) (27). In all, 34% of hospitalized patients ulti-
mately died. It is highly possible that some of the difference
in outcomes was influenced by the extent of cross-reactive
CTL memory.
Materials and Methods
Donors and PBMC Isolation. PBMCs were obtained from 52 donors: HLA-
A*0101+(n = 7 donors), A*0201+ (n = 9 donors), A*0301+ (n = 8 donors),
B*2705+ (n = 4 donors), B*0702 (n = 7 donors), B*5701 (n = 3 donors),
B*1801 (n = 3 donors), B*0801 (n = 5 donors), A*6801 (n = 3 donors), B*2402
(n = 3 donors), and B*15:01 (n = 3 donors) healthy individuals, after in-
formed consent was obtained. HLA genotyping was done at the Victorian
Transplant and Immunogenetics Service (West Melbourne, Australia). The
experiments were conducted according to the Australian National Health
and Medical Research Council Code of Practice and approved by the Uni-
versity of Melbourne Human Ethics Committee.
Epitope Conservation Analysis. H7N9 NP and M1 proteins sequences from the
Global Initiative on Sharing All Influenza Data (GISAID, www.gisaid.org) and
the epitope data from the Immune Epitope Database (www.immuneepitope.
org, accessed July 2013) were used to map antigenic CTL regions within
the immunogenic internal influenza proteins NP (76 epitopes) and M1
(39 epitopes), as described in SI Materials and Methods.
T-Cell Restimulation, Intracellular Cytokine Assay, and Tetramer Staining.
PBMCs were stimulated with NP- and M1-derived peptides for 10 d, fol-
lowed by the analysis of influenza-specific CTLs by a 5-h ICS or tetramer
staining, as described in SI Materials and Methods. Based on the conserva-
tion sequence analysis (Tables S2–S7), CTL reactivity to H7N9 was assessed to
a total of 39 NP and 1 M1 immunogenic peptides: the conserved M158, 8
conserved NP peptides, 7 H7N9 unique, and 26 variable NP peptides.
Protein Expression, Purification, Crystallization, and Thermal Stability. HLA-
A*0101–soluble HLA1 heterodimers containing NP44 peptides were pre-
pared, crystallized, and structures solved as described in SI Materials and
Methods. The coordinates have been submitted to the Protein Data Bank
(PDB) (ID codes 4NQV for NP44-A1 and 4NQX for NP44-S7N. Molecular
graphics representations were created using PyMol (28). To assess the effect
of peptide mutations, we tested the stability of each pHLA complex (29)
using a thermal shift assay (SI Materials and Methods).
Phylogenetic Analysis and Deduction of Ancestral Nonsynonymous Substitutions.
Maximum likelihood analysis was performed for the full protein coding genes
of the NP andM1 using the general time reversible substitutionmodel with the
γ-shaped rate variation in RaXML v7.7 (30). Ancestral nonsynonymous sub-
stitutions along the branches of the NP and M1 protein gene trees were de-
duced using the baseml program in PAML.
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